{"classes":[{"categories":[{"measurements":[{"comment":"Lower and upper limit of confidence intervals (CI) could not be estimated due to limited number of events and censoring. The Median was estimated because the longest observed participant event crossed 50%.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"38.6"},{"comment":"Data for median and upper limit of CI were not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"8.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. CR and PR are defined in OM#1. PD is defined in OM#6.\n\nKaplan-Meier (KM) estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEDIAN","populationDescription":"Participants with OR in the Full Analysis Set with available data were analyzed","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Duration of Response (DOR) by Central Assessment","type":"SECONDARY","unitOfMeasure":"months"}